The Food and Drug Administration has approved aripiprazole
lauroxil, a long-acting injectable atypical antipsychotic, for the treatment of adults with schizophrenia.
2015 a contract notice Aripiprazole
tablet products, in more detail in the tender dossier.
Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aripiprazole
Oral Solution 1 mg/mL, the generic version of the antidepressant drug ABILIFY[sup.
Risperidone and aripiprazole
have been studied in developmentally disabled and autistic patients and are approved for irritability associated with autism, but studies of newer agents are limited.
is a second-generation antipsychotic with a unique mechanism of action and, therefore, has a distinct side effect profile including akathisia (restlessness), headache, asthenia (weakness), and agitation (Heller et al.
Efficacy was demonstrated in a 12-week randomized, double-blind, placebo-controlled study, which showed treatment with Abilify Maintena, with concomitant oral aripiprazole
for the first two weeks, significantly improved symptoms with an acceptable safety and tolerability profile in adult patients experiencing an acute relapse of schizophrenia.
Steffens, who didn't participate in the duloxetine trial, highlighted another encouraging development in the treatment of late-life depression: a pooled subgroup analysis he and other investigators conducted using the data from three similar 14-week, prospective, randomized, doubleblind trials of adjuvant aripiprazole
(Abilify), compared with second-line antidepressant therapy in patients with major depressive disorder who had an incomplete response to standard antidepressant therapy.
com/research/cw7xqm/investigation) has announced the addition of the "Investigation Report on China's Aripiprazole
Market, 2009-2018" report to their offering.
Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole
in a once-monthly formulation.
anovel atypical antipsychotic, is being administered to children and adolescents for the management of mood instability, aggression, and psychosis.
Cooper in Trenton, NJ, upheld a patent that covers aripiprazole
, the key ingredient in the drug.
Christoph Correll and his team at Zucker Hillside Hospital in Glen Oaks, New York, monitored 257 children between the ages of 4 and 19 who were taking medications such as risperidone (Risperdal[R]), quetiapine (Seroquel[R]), aripiprazole
(Abilify[R]), and olanzapine (Zyprexa[R]).